私募调研勤字当头 聚焦“硬科技”“大健康”

Group 1 - In August, private equity firms conducted over 6,000 A-share company research activities, reflecting a significant increase of over 200% month-on-month, indicating a positive market sentiment among private equity institutions [1][2] - The pharmaceutical and biotechnology sector became the most favored area for private equity research in August, with 1,095 research activities, surpassing the computer sector from July [2][4] - Key companies such as Mindray Medical received the highest attention with 117 research activities, while stocks like Crystal Optoelectronics and Feikai Materials saw significant price increases of 33.11% and 23.41% respectively [2][3] Group 2 - Private equity institutions are focusing on "hard technology" and "big health" sectors, emphasizing high elasticity targets and leading companies in niche industries [4][5] - The increase in research activities in the pharmaceutical sector is attributed to reasonable overall valuations and improvements in innovative drug policies and industry fundamentals [4][5] - Smaller private equity firms, particularly those with assets under management below 500 million, have been notably active, with Shenzhen Shangcheng Asset leading with 143 research activities [3][6] Group 3 - The average stock position of domestic equity private equity firms was 75.55% as of August 22, showing a slight increase, indicating a continued positive positioning despite market fluctuations [7] - The focus on companies with core competitiveness and innovation capabilities suggests that private equity firms prioritize safety margins and certainty in their stock selection [5][6] - Research data serves as a leading indicator for investment trends, with heightened interest in sectors like pharmaceuticals and electronics, which may present structural investment opportunities [6][7]